BRIEF published on 03/04/2024 at 08:05, 8 months 17 days ago Defence Therapeutics Gains Significant US Patent for Cancer-Killing AccuTOX® Technology Cancer Treatment Defence Therapeutics AccuTOX® Technology US Patent Antibody-drug Conjugates
PRESS RELEASE published on 03/04/2024 at 08:00, 8 months 17 days ago DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY Defence Therapeutics Inc. is granted a broad U.S. patent for its innovative cancer-killing AccuTOX technology, potentially providing market exclusivity until late 2042 Defence Therapeutics Inc. Broad U.S. Patent AccuTOX Technology Cancer-killing Market Exclusivity
PRESS RELEASE published on 11/07/2023 at 08:00, 1 year ago DEFENCE THERAPEUTICS KEY PLATFORM PATENT ACCEPTED BROADLY COVERING VACCINE TECHNOLOGY
PRESS RELEASE published on 10/25/2023 at 08:00, 1 year ago DEFENCE’S ACCUTOX® AND ANTIGEN CROSS-PRESENTATION: DISCOVERY LEADS TOWARDS THE DEVELOPMENT OF A GROUDNBREAKING PLATFORM
PRESS RELEASE published on 10/18/2023 at 08:00, 1 year 1 month ago Defence Therapeutics Inc.: DEFENCE’S NOVEL ACCUTOXTM CONTINUES TO SURPRISE ON RESULTS AGAINST CANCER
PRESS RELEASE published on 10/17/2023 at 08:00, 1 year 1 month ago Defence Therapeutics Inc.: DELIVERY OF ENCAPSULATED ACCUTOXTM-CHITOSAN NANOPARTICLES TRIGGERS COMPLETE TUMOR REGRESSION IN ANIMALS WITH PRE-ESTABSLIHED SOLID LYMPHOMA
PRESS RELEASE published on 10/10/2023 at 08:00, 1 year 1 month ago DEFENCE ANNOUNCES PEER-REVIEWED PUBLICATION OF ITS PRECLINICAL DATA ON ACCUM® AS AN ANTI-CANCER MOLECULE IN THE JOURNAL OF CANCER SCIENCE
PRESS RELEASE published on 09/25/2023 at 08:00, 1 year 1 month ago DEFENCE’S ACCUM®-mRNA LIPID NANOPARTICLES ELICIT ANTIBODY RESPONSE 2X STRONGER THAN STANDARD mRNA VACCINES
PRESS RELEASE published on 09/12/2023 at 08:00, 1 year 2 months ago DEFENCE’S BROAD AND VERSATILE ACCUM® TECHNOLOGY PLATFORM FOCUS ON CANCER THERAPEUTICS
PRESS RELEASE published on 09/05/2023 at 08:00, 1 year 2 months ago DEFENCE’S INNOVATIVE THERAPEUTICS FEATURED ON VIEWPOINT WITH DENNIS QUAID
Published on 11/21/2024 at 22:05, 1 hour 6 minutes ago Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 1 hour 21 minutes ago Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 2 hours 56 minutes ago Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 3 hours 1 minute ago For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform
Published on 11/21/2024 at 20:00, 3 hours 11 minutes ago Victory for New York Homeowners: Petroff Amshen LLP Blocks Lender’s Repeated Foreclosure Attempt
Published on 11/21/2024 at 19:01, 4 hours 10 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 4 hours 35 minutes ago Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 5 hours 12 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 5 hours 19 minutes ago LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 5 hours 20 minutes ago 2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.
Published on 11/21/2024 at 06:58, 16 hours 13 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 3 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 5 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 5 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 15 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
